Re-engineering the innovator-clinic interface for adoption of advanced therapies

Tweetable abstract The cost of clinical adoption of advanced therapies must include the impact of any shortfall in 'institutional readiness'. This paper proposes wider use of business process engineering accompanied by activity-based cost analysis to quantify the cost of such impact. The relationship between regenerative medicine innovators and the clinics that will use their inventions continues to evolve. In the UK, the Advanced Therapy Treatment Centres exemplify this. The agents in the value chain are becoming collaborators in a shared innovation process. This paper proposes a larger role for systems engineering in this change and a cost-based representation of institutional readiness in designing suitable operational models for clinical adoption. The proposed approach places this value in a whole-lifetime cost framework. The current value for the adoption process can then be estimated for comparison with the sum of the adoption costs, the costs of operating at steady state and, if need be, replacement costs at end of life of the innovation.

Automated summary

This paper suggests considering the impact of institutional unreadiness on the cost of clinical adoption of advanced therapies, and recommends using business process engineering and activity-based cost analysis to quantify these costs. The relationship between regenerative medicine innovators and clinics is evolving, with Advanced Therapy Treatment Centres in the UK as an example. The various agents in the value chain are becoming collaborators in a shared innovation process.